Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 42.86 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $17.96 million which missed the analyst consensus estimate of $19.47 million by 7.75 percent. This is a 21.19 percent increase over sales of $14.82 million the same period last year.